Reaction
Developmental Hip Dysplasia reporting signals
As of the last recalculation, Developmental Hip Dysplasia appears in 823 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is LAMOTIRIGINE (PRR 38.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lamotirigine | 97 | 38.7 | 38.7 |
| Lamotrigine Extended-Release | 97 | 38.7 | 38.7 |
| Lamotrigine Chewable Dispersible | 97 | 38.7 | 38.7 |
| Valproic Acid | 40 | 33.7 | 33.7 |
| Levetiracetam In Sodium Chloride | 90 | 32.9 | 32.9 |
| Levetiracetam Oral | 90 | 32.9 | 32.9 |
| Levetiracetam Injection | 90 | 32.9 | 32.9 |
| Efavirenz | 13 | 29.9 | 30.0 |
| Ampicillin | 9 | 27.8 | 27.8 |
| Ampicillin Sodium | 9 | 27.8 | 27.8 |
| Progesterone | 24 | 27.3 | 27.3 |
| Misoprostol | 9 | 23.6 | 23.6 |
| Clobazam | 21 | 22.3 | 22.3 |
| Lamotrigine | 100 | 21.7 | 21.7 |
| Levetiracetam | 100 | 21.4 | 21.4 |
| Tenofovir Disoproxil Fumarate Tablets | 7 | 20.7 | 20.7 |
| Norepinephrine | 7 | 16.7 | 16.7 |
| Lamivudine Oral | 16 | 16.3 | 16.3 |
| Oxcarbazepine | 20 | 15.9 | 15.9 |
| Zidovudine | 8 | 15.3 | 15.3 |
| Lamivudine | 17 | 14.2 | 14.2 |
| Norepinephrine Bitartrate | 8 | 14.2 | 14.2 |
| Lacosamide | 20 | 13.9 | 13.9 |
| Ifosfamide | 9 | 10.7 | 10.7 |
| Baricitinib | 4 | 10.5 | 10.5 |
| Nicotine Polacrilex | 15 | 10.1 | 10.1 |
| Peginterferon Beta-1A | 4 | 7.8 | 7.8 |
| Somatropin | 18 | 6.3 | 6.3 |
| Palivizumab | 3 | 5.0 | 5.0 |